Almirall
Almirall, S.A., a prominent global pharmaceutical company headquartered in Barcelona, Spain, has established itself as a leader in the dermatology and respiratory sectors since its founding in 1943. With a strong presence across Europe and the United States, Almirall focuses on developing innovative treatments that address unmet medical needs. The company’s core offerings include prescription medications and advanced therapies, particularly in dermatology, where it is renowned for its unique formulations and patient-centric approach. Almirall has achieved significant milestones, including strategic partnerships and a robust pipeline of products that enhance its market position. Recognised for its commitment to research and development, Almirall continues to make strides in improving patient outcomes and advancing healthcare solutions globally.
DitchCarbon Score
How does Almirall's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Almirall's score of 86 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Almirall's reported carbon emissions
In 2024, Almirall reported total carbon emissions of approximately 147,641,000 kg CO2e. This figure includes 5,742,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 3,752,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. The majority of their emissions, about 141,899,000 kg CO2e, fall under Scope 3, which includes all other indirect emissions in the value chain. Almirall has set ambitious climate commitments, aiming for a 50% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2030, using 2019 as the baseline year. Additionally, they plan to reduce Scope 3 emissions by 28% by the same year. Long-term, the company is committed to achieving a 90% reduction in total emissions across all scopes by 2050. The company is also dedicated to sourcing 100% renewable electricity annually through 2030, reinforcing its commitment to sustainability and climate action. These targets align with the Science Based Targets initiative (SBTi) and reflect Almirall's proactive approach to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 6,864,000 | 000,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 6,305,000 | - | 000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 62,838,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Almirall is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
